Ankylosing Spondylitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for ankylosing spondylitis. 90 active patents protecting 7 drugs from 3+ originators. First major cliff: 2030. Daily refresh.

7
Approved drugs
90
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Ankylosing Spondylitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. (originally Searle/Pharmacia) 37 patents Generic (originally Schering) 33 patents Hisamitsu Pharmaceutical Co., Inc 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating ankylosing spondylitis. Each bar = one year. Y-axis scaled to peak year (30 patents).

17
27
3
28
9
29
30
30
1
31
5
32
4
33
7
34
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Celebrex
celecoxib
 Pfizer Inc. (originally Searle/Pharmacia) 13 51 — 2030-04-19
Indocin Sr
INDOMETHACIN
 — 6 56 — 2030-04-23
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8946292 Arthrotec method of use 80 2027-03-22
8563613 Arthrotec method of use 80 2027-10-17
8871809 Arthrotec method of use 80 2027-10-17
8168218 Deltasone method of use 80 2028-01-07
8252838 Arthrotec method of use 80 2028-04-21
11478488 Celebrex method of use 76 2030-04-19
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9132110 Arthrotec method of use 75 2027-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10245276 Celebrex composition of matter 10 2030-04-19
8598152 Celebrex composition of matter 10 2030-04-19
9012440 Celebrex composition of matter 10 2030-04-19
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23

Related